REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,094,225 shares of the biotechnology company’s stock after purchasing an additional 5,574 shares during the period. Geode Capital Management LLC owned approximately 2.21% of REGENXBIO worth $8,460,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after buying an additional 1,659,206 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares in the last quarter. Norges Bank acquired a new stake in shares of REGENXBIO during the fourth quarter valued at about $3,474,000. Hennion & Walsh Asset Management Inc. increased its position in shares of REGENXBIO by 8.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock worth $1,273,000 after acquiring an additional 13,014 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of REGENXBIO in the fourth quarter worth about $1,062,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. The Goldman Sachs Group cut their price target on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. Raymond James assumed coverage on shares of REGENXBIO in a report on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective for the company. Finally, Morgan Stanley boosted their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.63.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $8.90 on Thursday. REGENXBIO Inc. has a 1-year low of $5.04 and a 1-year high of $17.52. The company’s fifty day moving average is $6.84 and its two-hundred day moving average is $8.12. The stock has a market capitalization of $445.94 million, a price-to-earnings ratio of -1.77 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.70 million. Sell-side analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.